COURT-RULING filed Aug 23, 2026 at 20:00 ET
Merck lost its constitutional challenge to the IRA's Medicare Drug Price Negotiation Program in D.C. District Court. The court granted summary judgment to the government on all claims, rejecting Merck's arguments that the program constitutes an uncompensated taking, compels speech, or imposes unconstitutional conditions. This ruling, consistent with multiple circuit court decisions, removes a key legal obstacle to price negotiation on Merck's drug Januvia and other selected drugs, though the practical revenue impact depends on the negotiated price and Merck's participation decision. The stock has already rallied significantly in recent weeks, suggesting the market had largely discounted this outcome, and the ruling is subject to appeal to the D.C. Circuit, where Merck may seek a stay pending appeal.